Blog

Camilla Zimmermann: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults with Cancer

Photo: depositphotos.com

Jun 10, 2025, 14:52

Camilla Zimmermann: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults with Cancer

Camilla Zimmermann, Head of the Division of Palliative Care at the Princess Margaret Cancer Centre, posted on X:

“Urgent need for updated guidelines on Systemic Anticancer Therapy use at End of Life: Our study of 68,000+ patients found use of novel SACT at EOL, including immunotherapy, was associated with indicators of poor-quality.”

Title: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer

Authors: Javaid Iqbal, Rahim Moineddin, Kieran L. Quinn, Christopher M. Booth, Craig C. Earle, Stephanie Lheureux, Robert Grant, Jenny Lau, Lisa W. Le, Peter Tanuseputro, James Downar, Gary Rodin, Hsien Seow, Jillian Tsai, Robert A. Fowler, Breffni Hannon, Monika K. Krzyzanowska, Camilla Zimmermann

Read The Full Article at Journal of Clinical Oncology.

Camilla Zimmermann: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults with Cancer

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Blog

OncoDaily

Blog

Camilla Zimmermann: Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults with Cancer

“Urgent need for updated guidelines on Systemic Anticancer Therapy use at End of Life: Our study of 68,000+ patients found use of novel SACT at EOL, including immunotherapy, was associated with indicators of poor-quality.”